DEA OKs Company to Import Coca Leaves for 'Legit' Use
Published Date: 3/10/2025
Notice
Summary
Stepan Company wants to become an official importer of certain controlled substances, like coca leaves. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 9, 2025. This move could affect businesses handling these substances and involves careful government review, but no direct costs are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Stepan applied to import coca leaves
Stepan Company applied on January 31, 2025 to be registered as an importer of coca leaves (controlled substance code 9040, Schedule II). Registered bulk manufacturers and other applicants may submit electronic comments, objections, or a written request for a hearing on or before April 9, 2025.
Import registration excludes finished dosage forms
If approved, the registration would authorize Stepan to import coca leaves for bulk manufacture but explicitly will not authorize the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-03765, Proposed Agency Information Collection Activities; Comment Request
The Federal Railroad Administration wants your thoughts on a new info collection plan that helps them do their job better. If you’re involved with railroads or just curious, you can comment by May 9, 2025. This won’t cost you money but might change how often some paperwork is done.
Next: 2025-03767, Presidential Declaration of a Major Disaster for Public Assistance Only for the Commonwealth of Kentucky
The President declared a major disaster for parts of Kentucky hit by storms, flooding, and mudslides starting February 14, 2025. Non-profit groups in 10 counties can now apply for low-interest disaster loans to help recover, with physical damage loan applications due by May 5 and economic injury loans by December 4. This declaration means faster aid and financial support to get communities back on their feet!